Fibroblast activation protein-targeted radioligand therapy in various types of cancer: Background, clinical studies, and future development
Advances in Radiotherapy & Nuclear Medicine · 24.10.2023 · 1667
DOI: 10.36922/arnm.1667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Radiotherapy & Nuclear Medicine, online erschienen am 24.10.2023. Verfasst von Yizhen Pang und 6 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cancer is the leading cause of mortality worldwide. The proliferation and viability of cancer cells are intricately related to the complex tumor microenvironment in which they reside. Cancer-associated fibroblasts (CAFs) play a pivotal role in multiple stages of tumorigenesis, including tumor growth, invasion, metastasis, and resistance to treatment, through intricate crosstalk with tumor and immune cells. Targeted radionuclide therapy involves the systemic administration of small molecule drugs labeled with β-emitting or α-emitting radioisotopes, allowing precise targeting of tumor sites and delivering radiation directly to the tumor. Prostate-specific membrane antigen-targeted radioligand therapy (RLT) and somatostatin receptor-targeted peptide receptor radionuclide therapy (PRRT) have demonstrated favorable safety profiles and significant antitumor efficacy, leading to their approval by the Food and Drug Administration. Recently, the utilization of theranostic approaches that target overexpressed fibroblast activation proteins (FAPs) within the CAFs of the tumor stroma has demonstrated encouraging preliminary outcomes. This review aims to provide a concise summary of current clinical research outcomes and the applications of RLT based on FAP inhibitors in the context of solid tumors.
Zitieren
APA
Pang, Y., Zhao, L., Chen, J., Xu, W., Cai, J., Chen, H., & Lin, Q. (2023). Fibroblast activation protein-targeted radioligand therapy in various types of cancer: Background, clinical studies, and future development. Advances in Radiotherapy & Nuclear Medicine, 0(0), 1667. https://doi.org/10.36922/arnm.1667
Vancouver
Pang Y, Zhao L, Chen J, Xu W, Cai J, Chen H, et al. Fibroblast activation protein-targeted radioligand therapy in various types of cancer: Background, clinical studies, and future development. Advances in Radiotherapy & Nuclear Medicine. 2023;0(0):1667. doi:10.36922/arnm.1667
BibTeX
@article{Pang2023,
author = {Pang, Yizhen and Zhao, Liang and Chen, Jianhao and Xu, Weizhi and Cai, Jiayu and Chen, Haojun and Lin, Qin},
title = {Fibroblast activation protein-targeted radioligand therapy in various types of cancer: Background, clinical studies, and future development},
journal = {Advances in Radiotherapy & Nuclear Medicine},
year = {2023},
volume = {0},
number = {0},
pages = {1667},
doi = {10.36922/arnm.1667}
}
EUVIMED